Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Renalytix AI stock

Learn how to easily invest in Renalytix AI stock.

Renalytix AI is a health information services business based in the US. Renalytix AI shares (RNLX) are listed on the NASDAQ and all prices are listed in US Dollars. Renalytix AI employs 51 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Renalytix AI

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RNLX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Renalytix AI stock price (NASDAQ: RNLX)

Use our graph to track the performance of RNLX stocks over time.

Renalytix AI shares at a glance

Information last updated 2022-07-03.
Latest market close$2.56
52-week range$2.23 - $34.98
50-day moving average $4.31
200-day moving average $12.23
Wall St. target price$25.33
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.21

Buy Renalytix AI shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
eToro
Stocks, ETFs, Cryptocurrency
$0
$10
$10
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$0
$1
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0
$0
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Axos Bank Self Directed Investing
Stocks
$0
$1,000
$150
when you open an account and deposit at least $1500.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Renalytix AI stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Renalytix AI price performance over time

Historical closes compared with the close of $2.56 from 2022-07-01

1 week (2022-06-28) -36.00%
1 month (2022-06-03) -43.98%
3 months (2022-04-05) -61.15%
6 months (2022-01-05) -83.12%
1 year (2021-07-02) -90.92%
2 years (2020-07-01) N/A
3 years (2019-07-01) N/A
5 years (2017-07-01) N/A

Renalytix AI financials

Revenue TTM $2.4 million
Gross profit TTM $633,000
Return on assets TTM -29.7%
Return on equity TTM -49.23%
Profit margin 0%
Book value $1.98
Market capitalisation $95.7 million

TTM: trailing 12 months

Renalytix AI share dividends

We're not expecting Renalytix AI to pay a dividend over the next 12 months.

Renalytix AI share price volatility

Over the last 12 months, Renalytix AI's shares have ranged in value from as little as $2.23 up to $34.98. A popular way to gauge a stock's volatility is its "beta".

RNLX.US volatility(beta: 1.59)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Renalytix AI's is 1.5915. This would suggest that Renalytix AI's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Renalytix AI overview

Renalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021.

Frequently asked questions

What percentage of Renalytix AI is owned by institutions?
Currently 17.823% of Renalytix AI shares are held by institutions.
How many people work for Renalytix AI?
Latest data suggests 51 work at Renalytix AI.
When does the fiscal year end for Renalytix AI?
Renalytix AI's fiscal year ends in June.
Where is Renalytix AI based?
Renalytix AI's address is: 1460 Broadway, New York, NY, United States, 10036
What is Renalytix AI's ISIN number?
Renalytix AI's international securities identification number is: US75973T1016

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site